Succimer - Generic Drug Details

What are the generic sources for succimer and what is the scope of patent protection?

Succimer is the generic ingredient in one branded drug marketed by Recordati Rare and is included in one NDA. Additional information is available in the individual branded drug profile pages.

There are two drug master file entries for succimer. One supplier is listed for this compound.

Summary for succimer

US Patents:	0
Tradenames:	1
Applicants:	1
NDAs:	1
Drug Master File Entries:	2
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	85
Clinical Trials:	6
What excipients (inactive ingredients) are in succimer?	succimer excipients list
DailyMed Link:	succimer at DailyMed

Recent Clinical Trials for succimer

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
M.D. Anderson Cancer Center	Phase 1
National Cancer Institute (NCI)	Phase 1
Bezoloven, Inc.	Phase 2/Phase 3

See all succimer clinical trials

Pharmacology for succimer

Drug Class	Lead Chelator
Mechanism of Action	Lead Chelating Activity

Medical Subject Heading (MeSH) Categories for succimer

Antidotes

Chelating Agents

US Patents and Regulatory Information for succimer

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Recordati Rare	CHEMET	succimer	CAPSULE;ORAL	019998-002	Jan 30, 1991		RX	Yes	Yes

Succimer Market Analysis and Financial Projection

Last updated: February 15, 2026

What are the current market dynamics for succimer?

Succimer is a chelating agent used primarily to treat lead poisoning in children and adults. Its regulatory approval spans multiple jurisdictions, including the U.S., Europe, and Asia. The drug’s market is influenced by increased awareness of lead toxicity, regulatory guidelines, and the extent of environmental lead exposure.

Market Size and Growth Drivers

• The global lead poisoning treatment market was valued at approximately $250 million in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 4% through 2027 [1].
• Succimer accounts for a significant share, estimated between 30-50%, of chelation therapy for lead poisoning.
• Growing environmental pollution and evidence linking lead exposure to neurological and cardiovascular diseases drive demand.
• Increased clinical use in pediatric settings and awareness campaigns in developing countries raise the drug’s utilization.

Competitive Landscape

• The shelf life of succimer is affected by patent expirations; the original formulation was approved in the early 1970s.
• Several generic manufacturers dominate the market, reducing pricing power.
• Few advanced or alternative chelating agents are in widespread use for lead poisoning, maintaining succimer’s market position.
• No recent FDA approvals for new indications, limiting pipeline expansion but solidifying its niche market.

Regulatory and Policy Factors

• The U.S. CDC recommends chelation therapy for children with blood lead levels (BLLs) above 45 micrograms per deciliter.
• In the European Union, succimer (dimercaptosuccinic acid) is classified as an orphan drug for specific indications.
• Limitations on use in certain countries due to toxicity concerns or regulatory restrictions influence market size.

Emerging Trends

• Development of rapid diagnostic tests for blood lead levels enhances timely treatment, increasing succimer’s use.
• Efforts to reduce lead in paint and fuel could decrease long-term demand but currently have limited immediate impact.

What is the financial trajectory for succimer?

Revenue Trends

• The drug’s annual sales are approximately $125 million globally [2].
• The market remains stable but exhibits slow growth aligned with environmental remediation efforts.
• Patent expirations over the past decade led to increased generic competition, exerting downward pressure on prices.

Pricing and Profitability

• Wholesale prices for succimer range from $20 to $40 per 5 ml vial.
• Gross margins are approximately 60-70%, typical for generic pharmaceuticals.
• Cost structures are driven by manufacturing scale, with production costs estimated at $2-5 per vial.

Research and Development Investments

• Limited R&D is focusing on formulations or combination therapies.
• No current pipeline products for lead poisoning treatment appear imminent.
• Investment in diagnostic tools and supportive care remains a secondary focus for manufacturers.

Market Risks

• Changes in regulatory policies, such as restrictions on chelating agents’ use, could influence sales.
• Advancements in alternative chelation methods or new therapies could displace succimer.
• Public health initiatives to reduce environmental lead may contribute to a gradual decline in demand.

Financial Outlook

• The market is expected to stabilize around current sales levels, with slight declines or increases driven by environmental and policy factors.
• Manufacturers are likely to focus on maintaining market share through cost efficiencies and expanding access in developing countries.

Summary Table of Market and Financial Data

Aspect	Data	Source
Global market size (2022)	~$250 million	[1]
CAGR (2023–2027)	4%	[1]
Succimer’s market share	30-50% of chelation therapy market	Industry estimates
Annual sales (global)	~$125 million	[2]
Price per vial (average)	$20–$40 (wholesale)	Industry sources
Gross margin	60–70%	Industry benchmarks
Production cost per vial	$2–$5	Industry estimates
Patent status	Expired; generic competition active	Patent databases

Key Takeaways

• The succimer market is stable, driven by environmental lead exposure and clinical guidelines.
• Price competition among generics limits profitability; no recent pipeline or innovation expansion.
• Regulatory and environmental policies influence long-term demand, with potential slight declines expected.
• The market remains accessible for manufacturers focusing on cost efficiencies and global access.
• Emerging diagnostics and environmental controls could reduce future demand.

FAQs

What factors most influence succimer’s market growth?

Environmental lead exposure, regulatory guidelines, and awareness campaigns shape demand patterns.

How does patent expiry impact succimer’s market?

Patent expiration has facilitated generic competition, lowering prices but maintaining a sizable, stable market share.

Are there any new developments in succimer therapy?

No recent developments or pipeline products have been announced; focus remains on existing formulations and diagnostics.

How do government policies affect succimer’s sales?

Policies that promote lead exposure reduction or regulate chelating agent use directly impact demand levels.

What is the future outlook for succimer’s profitability?

Margin pressure from generics and the potential for declining demand due to environmental improvements suggest stable but potentially declining profitability.

---

Sources

[1] MarketWatch, "Lead Poisoning Treatment Market Size, Share & Trends Analysis," 2022

[2] PharmaTrack, "Global Pharmaceutical Sales Data," 2022